Antibiotic Resistance in Escherichia coli Iron Transport Mutants by Brandt, Madeline
Bowling Green State University 
ScholarWorks@BGSU 
Honors Projects Honors College 
Fall 12-11-2017 
Antibiotic Resistance in Escherichia coli Iron Transport Mutants 
Madeline Brandt 
mbrandt@bgsu.edu 
Follow this and additional works at: https://scholarworks.bgsu.edu/honorsprojects 
 Part of the Chemicals and Drugs Commons, Epidemiology Commons, Medical Education Commons, 
and the Pharmacy and Pharmaceutical Sciences Commons 
Repository Citation 
Brandt, Madeline, "Antibiotic Resistance in Escherichia coli Iron Transport Mutants" (2017). Honors 
Projects. 419. 
https://scholarworks.bgsu.edu/honorsprojects/419 
This work is brought to you for free and open access by the Honors College at ScholarWorks@BGSU. It has been 
accepted for inclusion in Honors Projects by an authorized administrator of ScholarWorks@BGSU. 
 
 
Antibiotic resistance in Escherichia coli iron transport mutants 
 
Madeline Brandt 
mbrandt@bgsu.edu 
 
Dr. Raymond Larsen 
Biological Sciences 
 
Dr. Philip Welch 
Public and Allied Health 
 
 
 
Abstract: 
  
 Studies previously completed on Escherichia coli mutants suggested the possibility of 
iron uptake as an influence on the antibiotic resistance seen in different strains.  The research 
focused on the TonB energy transduction system and its contributions to efflux-mediated 
antibiotic resistance.  To test the hypothesis that iron uptake has an influence on antibiotic 
resistance in Escherichia coli, the sensitivity to a variety of antibiotics was evaluated in strains of 
E. coli lacking genes that relate to the uptake of iron or the efflux system that is necessary for the 
uptake of iron.  To test the efflux systems TolC and TonB were compared with the strains that 
had those genes removed and then tested against three different antibiotics.  No significant 
correlation was found between the ∆tolC and ∆tonB	mutants.		Understanding	the	efflux	systems,	
outer	membrane	integrity,	energy	transduction	systems,	and	iron	uptake	of	the	gram-negative	
E.	coli	is	important	for	the	antibiotic	resistance	that	is	becoming	more	common	in	the	
healthcare	system	and	public	health. 
 
 
  
Introduction: 
Drug resistance is becoming a very common issue in today’s healthcare and has reached 
alarming levels in many parts of the world [6].  Antibiotic resistance (ABR) is becoming more 
common because of the misuse or overuse of antibiotics, which allows the bacteria to become 
resistant when they survive the initial treatment and are allowed time to reproduce.  This 
bacterial evolution is a natural process and therefore can only be slowed rather than stopped 
completely.  Gram-negative bacteria tend to be especially threatening as they are most 
commonly found to be resistant to more common drugs [5]. Drug resistance occurs when one of 
four things happen;  bacterial cells can adapt and form a better outer membrane that is more 
selective in what it allows to pass through into the cytoplasm and inner cell and what it blocks 
from passage, over-expressed efflux pumps around the bacterial cell membrane that pump out 
antibiotic as it enters-efflux, drug resistant bacteria break down the drug before it causes harm to 
the cell, or the target of the antibiotic drugs is changed due to a deficiency of nutrients being 
made available to the cell because of the deletion of specific genes that are responsible for 
bringing those nutrients in to the cell.  The least likely possibility for our specific experiment 
regarding drug resistant E. coli could be that the cell is breaking down the drug before it causes 
harm to the cell.  This is unlikely because E. coli is not capable or known to be able to break 
down antibiotics as a form of resistance.  In this project, we are focusing in on the deficiency of 
nutrients and the resulting shift to focus the resources of the cell. 
Gram-negative bacteria such as Escherichia coli have a cytoplasmic and outer membrane 
with a periplasmic space between.  The purpose of the outer membrane is to protect bacteria 
from environmental invaders.  The outer membrane also limits the ability of nutrients to enter the 
cell, which can also cause stress and starvation for the bacterial cell [7][8][9][10].  Nutrients and 
invaders of the cell can cross the outer membrane of bacteria in one of three different ways; 
diffusion through stereospecific protein porins, diffusion through non-specific protein porins, and 
active transport with mediation from high-affinity outer membrane receptor proteins [8].  The 
∆tonB gene is known to be responsible for transporting Vitamin B12 and iron across the cell 
membrane.  These molecules are too large to pass through porin channels the way amino acids, 
sugars, and short peptides do[7][8].  The TonB system transports energy from the cytoplasmic 
membrane to the outer membrane of the cell via an unknown mechanism [9]. 
 
Past Research: 
 In the 1990s, researchers reported that the deletion of the TonB gene in Pseudomonas 
aeruginosa bacteria was related to drug resistance.  They hypothesized the drug resistance 
correlation with the deletion of the TonB gene was due to TonB being required to energize the 
drug efflux and transport system [1][2].  The TonB energy transduction system contributes to 
efflux-mediated antibiotic resistance through the energization of efflux systems.  It is well 
established that TonB is important in energizing the transport system, most importantly in iron 
transport, which brings energy into the cell.  The research concluded by highlighting how TonB 
bacteria are compromised in their ability to transport iron via siderophores because of their lack 
of the iron transport system.  Even in iron rich conditions the TonB mutants are limited in their 
iron transport capabilities [4].   
This project is a continuation of the research project “TonB not directly related to efflux 
of antibiotics in Escherichia coli” completed by Amber Gombash.  The purpose of Amber’s 
study was to follow up on the research completed on the Pseudomonas aeruginosa bacteria in 
the 1990s using TonB mutants.  Her study tested the hypothesis that enhanced sensitivity of 
∆tonB strains of Escherichia coli to antibiotics was due to the energization of efflux systems.  
This was tested by using differing strains of bacteria lacking genes encoding the Acr efflux 
system, the universal outer membrane efflux portal TolC, and TonB [3].  Comparisons made 
using the Tol system did not include the chance that increased sensitivity of the TonB strains 
included disruption of the barrier function of the outer membrane[3].  The study concluded that 
efflux mechanisms are important for erythromycin drug resistance and efflux mechanisms and 
barrier functions are important for rifampicin resistance.  However, it was found that efflux is 
unlikely to be important for vancomycin resistance [3].  Overall, the question remaining after the 
conclusion of the experiment was whether or not TonB mutants are more susceptible to 
antibiotics due to the iron starvation of the cell rather than the efflux role that TonB plays in E. 
coli.  
The goal of the project I will be completing is to determine whether efflux-mediated 
antibiotic resistance is directly affected by the TonB energy transduction system or whether 
changes in iron availability to the different strains of E. coli affect the susceptibility of E. coli to 
antibiotics.  By changing the genes of the W3110 “wildtype” E. coli (refer to Table 1) that 
encode for aspects of the outer membrane of bacteria we can test whether the bacteria become 
more sensitive to the antibiotic without a specific gene.  We also would like to test whether it is 
instead just a lack of nutrients such as iron that are impacting the way that the bacteria are able to 
fight antibiotics.  By evaluating the sensitivity of different strains of Escherichia coli to specific 
antibiotics we can study the molecular mechanisms of antibiotic resistance.  Through learning 
more about microorganism resistance to antibiotics we can find better ways to fight multi-drug 
resistant bacterial strains.  This type of information is vital in today’s world with the many 
different antibiotic resistant strains of bacteria becoming more prevalent.  Learning about the role 
of these mutations in E. coli can help us transfer that information to other gram-negative 
bacteria, and therefore allow us to develop antibiotic drugs that will more efficiently fight the 
resistant bacteria. 
 
Materials and Methods: 
 
 Varying strains of mutated Escherichia coli were used to determine which of the strains 
were more antibiotic resistant and how their specific mutation correlated to that resistance.  The 
E. coli strains were narrowed down to the eight in Table 1 below; W3110 (Wildtype), RA 1084 
(∆tonB), RA 1054 (∆tolC), RA 1055 (∆acrA), RA 1056 (∆acrB), RA 1038 (∆tolA), RA 1083 
(∆fur), and JW 3352 (∆aroB).  The phenotypes of their mutations are explained in Table 1 as 
well and correlate to the conclusions drawn from the lab results.  
Table 1  
Strain Table 
Strain Genotype Phenotype 
W3110 Wildtype Wildtype; energy transduction 
RA 1084 ∆tonB Energy transduction 
RA 1054 ∆tolC  
Efflux RA 1055 ∆acrA 
RA 1056 ∆acrB 
RA 1038 ∆tolA Outer membrane integrity 
RA 1083 ∆fur Needed for iron uptake 
JW 3352 ∆aroB	 Iron repression, makes 
siderophore, without this gene 
too much iron is brought into the 
cell 
 
 
 Six specific strains were targeted over the course of the research.  Those strains were 
W3110, RA 1084, RA 1054, RA 1038, RA 1083, and JW 3352.  These six strains were cultured 
on agar plates under refrigeration.  A single colony of each strain was taken from the individual 
plates and placed in 5 milliliters of broth.  The six tubes were then left to incubate with shaking 
overnight.  To measure zones of inhibition in triplicate, one hundred microliters of each broth 
culture was pipetted into separate small test tubes with three milliliters of hot T-top agar to 
follow.  Immediately afterwards the cells suspended in T-top agar were poured onto T-top agar 
plates and evenly spread before the T-top cooled.  This was repeated three separate times for 
each of the six strains, once each for a triplicate measurement of erythromycin, vancomycin, and 
rifampicin.  Three separate disks were placed on each plate for the triplicate measurement.  The 
plates were then placed in the incubator at 37°C overnight and measured the next day for zones 
of inhibition.   
Fig. 1 Examples of zones of inhibition in a RA 1054 ∆tolC strain with discs of erythromycin 
 
 
 
Antibiotic discs 
 
 
 
Zone of inhibition—clear area where 
bacteria has been killed by the antibiotic and 
cannot grow 
 
 
Agar plate with TolC strain E.Coli growth 
This particular sample was done in triplicate on one tea top plate.  Zones of inhibition are 
measured in millimeters. 
 
 Following these measurements, further testing of the precise resistance for each strain 
was completed with serial fold dilutions.  First, the dilution was completed on the W3110 strain 
to determine which dilution of rifampicin would be enough to kill and prevent growth of the E. 
coli.  Nine test tubes were used.  20 microliters of rifampicin were placed into the first test tube 
with 2ml LB.  Each of the 8 successive tubes contained 1ml LB.  1ml LB mixed with the 20 
microliters of rifampicin was removed from the first tube via pipette and placed into the next 
tube and mixed.  This was then repeated down the line, with one tube left without rifampicin to 
remain a control.  10 microliters of the W3110 strain were added to each tube.  The tubes were 
then placed in an incubator with shaking overnight.  The next day the tubes were observed for 
bacterial growth.  Once the initial W3110 trial run was successful, the dilution was repeated with 
all six E. coli strains; W3110, RA 1038, RA 1054, RA 1083, JW	3352,	and	RA	1084.	
	
Results:	
	 The	results	for	each	strain	for	the	three	different	antibiotic	tests	are	shown	in	tables	2-4.		
In	Table	2,	the	zones	of	inhibition	for	erythromycin	were	fairly	even	across	the	board	with	the	
exception	of	∆tolC,	which	had	much	higher	zones	of	inhibition	and	a	much	higher	overall	mean. 
∆tolA	Also	had	a	slightly	higher	mean	for	the	zones	of	inhibition.	
	 Table 2: Zones of inhibition diameter measurements with mean and standard deviation 
calculations included for the erythromycin antibiotics against each of the E. coli strains. 
Erythromycin Zones of Inhibition 
Mutant Strain Trial 1 Trial 2 Trial 3 Mean 
∆tolA 10mm 11mm 11mm 10.6mm 
Standard Deviation: 0.18 0.08 0.08  
∆tolC 16mm 16mm 15mm 15.6mm 
Standard Deviation: 0.08 0.08 0.18  
∆fur 10mm 9mm 8mm 9mm 
Standard Deviation: 0.5 0 0.5  
∆tonB 9mm 8mm 9mm 8.6mm 
Standard Deviation: 0.08 0.18 0.08  
∆AroB 8mm 8mm 8mm 8mm 
Standard Deviation: 0 0 0  
W3110 9mm 10mm 9mm 9.6mm 
Standard Deviation: 0.18 0.08 0.18  
The results were similar in the triplicate trials with vancomycin shown in Table 3.  The 
mean zones of inhibition were all relatively similar in size for each of the strains except for in 
one, ∆tolA.			
Table 3: Zones of inhibition diameter measurements with mean and standard deviation 
calculations included for the vancomycin antibiotics against each of the E. coli strains. 
Vancomycin Zones of Inhibition 
Mutant Strain Trial 1 Trial 2 Trial 3 Mean 
∆tolA 14mm 14mm 14mm 14mm 
Standard Deviation: 0 0 0  
∆tolC 8mm 8mm 7mm 7.6mm 
Standard Deviation: 0.08 0.08 0.18  
∆fur 8mm 8mm 8mm 8mm 
Standard Deviation: 0 0 0  
∆tonB 8mm 8mm 9mm 8mm 
Standard Deviation: 0 0 0  
∆AroB 9mm 7mm 8mm 8mm 
Standard Deviation: 0.5 0 0.5  
W3110 9mm 9mm 9mm 9mm 
Standard Deviation: 0 0 0  
 
The zones of inhibition for the trials with the antibiotic rifampicin showed much larger 
zones of inhibition.  These results showed two specific strains standing out from the rest with 
significantly smaller zones of inhibition.  These strains were the wildtype W3110 and ∆AroB.   
  
Table 4: Zones of inhibition diameter measurements with mean and standard deviation 
calculations included for the rifampicin antibiotics against each of the E. coli strains. 
 
Rifampicin Zones of Inhibition 
Mutant Strain Trial 1 Trial 2 Trial 3 Mean 
∆tolA 21mm 20mm 21mm 20.7mm 
Standard Deviation: 0.17 0.4 0.17  
∆tolC 21mm 19mm 21mm 20.3mm 
Standard Deviation: 0.4 0.75 0.4  
∆fur 20mm 20mm 19mm 19.7mm 
Standard Deviation: 0.17 0.17 0.4  
∆tonB 21mm 21mm 20mm 20.7mm 
Standard Deviation: 0.17 0.17 0.4  
∆AroB 17mm 18mm 18mm 17.7mm 
Standard Deviation: 0.4 0.17 0.17  
W3110 16mm 16mm 15mm 15.7mm 
Standard Deviation: 0.17 0.17 0.4  
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Conclusion:	
	 The	∆tolC	mutant	lacking	the	efflux	mechanisms	showed	a	lack	of	resistance	to	
erythromycin	in	comparison	to	the	other	five	strains.		Efflux	mechanisms	are	important	to	
erythromycin	resistance	and	outer	membrane	integrity	is	important	for	vancomycin	resistance.		
Efflux	mechanisms	and	outer	membrane	integrity	are	important	for	rifampicin	resistance.		Loss	
of	integrity	of	the	membrane	in	mutants	such	as	∆tolA	resulted	in	less	resistance	to	the	
vancomycin	and	rifampicin	discs.		Loss	of	efflux	mechanisms	in	∆tolC	resulted	in	less	resistance	
to	erythromycin.	
	 It	has	been	suggested	that	TonB	may	drive	efflux	[1][2].		If	this	were	true	then	the	∆tonB	
mutant	should	have	a	similar	reaction	as	the	∆tolC	mutant	to	the	antibiotics.		This	was	not	the	
case	with	erythromycin	resistance	but	there	were	similar	measurements	found	in	the	
vancomycin	and	rifampicin	antibiotic	tests.		However,	research	still	cannot	confirm	that	those	
few	similarities	prove	that	TonB	drives	efflux	as	there	were	similarities	in	several	of	the	other	
mutant’s	measurements	as	well.			
	 In	the	tests	that	we	began	with	rifampicin	dilution,	∆tolC	was	consistently	the	most	
susceptible	(least	resistant)	in	both	trials.		More	trials	would	have	to	be	completed	to	allow	for	
more	accuracy	before	further	conclusions	are	drawn.	
	 TonB	is	known	to	be	important	for	iron	transport.		Iron	is	growth-limiting	and	important	
for	bacterial	virulence	[11].		Throughout	the	following	spring	semester	we	will	be	completing	
the	research	on	the	effect	iron	transport	has	on	the	Escherichia	coli	strains	and	their	resistance	
to	antibiotics.	
	 	
Discussion:	
	
	 This	research	focuses	on	the	antibiotic	resistance	issue	that	is	occurring	more	and	more	
often	in	bacteria	in	healthcare	settings.		It	is	vital	that	we	learn	more	about	these	resistance	
mutants	so	that	stronger,	more	effective	drugs	can	be	created	to	fight	the	resistant	bacteria.		
Gram-negative	bacteria	are	often	more	difficult	to	treat	and	more	dangerous	to	the	human	
body	because	of	the	resistant	nature	of	their	outer	membranes.		By	studying	gram-negative	
bacteria	such	as	E.	coli	we	can	learn	more	about	the	specific	mutations	that	lead	to	resistance	
and	adjust	the	drugs	needed	to	kill	them.		“The	only	reason	for	studying	a	pathogen	is	to	learn	
how	to	kill	it”	[12].			
	 Antibiotic	resistance	is	term	coined	for	bacteria	that	are	adapting	to	survive	previously	
effective	treatments.				The	CDC	has	levels	set	determining	the	threat	of	different	antibiotic	
resistant	strains	of	bacteria	[13].		The	threat	levels	vary	from	“concerning	threats”,	“serious	
threats”,	and	“urgent	threats.”		Bacteria	that	fall	under	“urgent	threats”	include	Clostridium	
difficile,	which	causes	life	threatening	diarrhea	and	occurs	most	commonly	in	hospitalized	or	
recently	hospitalized	patients.		Over	the	course	of	five	years	the	medical	costs	of	C.	difficile	
infections	could	be	up	to	$3.8	billion	and	15,000	deaths	are	directly	attributable	to	C.	difficile	
infections.		Another	“urgent	threat”	is	Carbapenem-Resistant	Enterobacteriaceae	or	CRE.		CRE	
is	resistant	to	all	or	nearly	all	antibiotics	we	have	today	and	nearly	half	of	those	who	get	
bloodstream	infections	from	CRE	bacteria	die	as	a	result	of	the	infection.		Lastly,	the	Neisseria	
gonorrhoeae	which	causes	the	sexually	transmitted	disease	(STD)	gonorrhea,	is	either	resistant	
or	has	reduced	susceptibility	to	the	top	four	drugs	that	would	initially	be	used	to	gonorrhea.			
	 Each	of	these	top	three	most	“urgent	threats”	have	one	thing	in	common—they	are	all	
gram-negative	bacteria.		This	is	why	any	research	completed	on	the	membrane	integrity	or	
antibiotic	susceptibility	on	gram-negative	bacteria	is	so	essential.		To	combat	ABR	the	CDC	
recommends	five	actions:	preventing	infection	(safe	food	handling,	hand	washing,	
immunizations),	preventing	the	spread	of	resistance	(use	of	antibiotics	only	when	necessary	
and	as	directed),	strategy	development	on	prevention	and	tracking,	improving	the	prescribing	
of	antibiotics	to	stop	unnecessary	use,	and	developing	new	antibiotics	and	diagnostic	testing	to	
replace	the	drugs	that	no	longer	work	[13].			
	 Research	and	development	of	antibiotics	must	target	gram-negative	bacteria.		One	
barrier	to	research	and	development	is	the	lack	of	incentive	for	pharmaceutical	companies.		
Antibiotic	research	and	development	requires	less	clinical	trial	and	development	time	than	any	
other	drug	[14].		In	order	to	combat	the	spread	of	antibiotic	resistance	we	need	new	and	
improved	drugs	that	will	knock	out	the	pathogen	completely,	rather	than	allow	the	resistant	
strains	to	survive.	
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